Connect with us


DR Congo approves “MANACOVID” as coronavirus vaccine



DR Congo approves “MANACOVID” as coronavirus vaccine

The Democratic Republic of Congo has approved the “MANACOVID” – an extractive of a local medical plants, as coronavirus vaccine after it reportedly successfully cured 300 positive cases.

The Luozi pharmaceutical research centre (CRPL), on Tuesday authorized the coronavirus vaccine to treat the viral infection in the country, the News Agency of Nigeria reported.

A statement issued in Kinshasa, the capital city, said the results were observed by three teams of doctors on 300 cases that tested positive to COVID-19.

All these cases proved negative with no symptoms and a good tolerance, within five days of treatment or 100 per cent recovery.

Approved on November 24, 2020, with a certificate of invention as evidence, “MANACOVID” is a product based on local medicinal plants.

It was discovered in March 2020 by Congolese chemist-doctor, Etienne Flaubert Batangu Mpesa, following his work with a team of pharmacist researchers, the statement said.

MANACOVID is one of three projects selected and recommended by the ministry of Scientific Research and Technologic innovation since 14 April, 2020, for clinical tests.

Read also: DR CONGO: WHO sets up panel to probe allegations of s*x abuse by aid workers

Before its approval, all the processes were respected, particularly the approval of the MANACOVID protocol by the National Health Ethics Committee (CNES).

The clinical tests were carried out from June to October 2020 through three independent teams of Congolese investigative doctors registered with the DRC Doctors Order under the coordination of a principal-investigator.

Pharmacist Etienne Flaubert Batangu Mpesa graduated at Lovanium University since 1971, now University of Kinshasa (UNIKIN). He became teacher of Pharmaceutical sciences at Montreal, Quebec/Canada University in 1980.

Mpesa, now chairman of the board of directors of CRPL, is the inventor of the products Manadiar (against amebic diarrhea) and Manalaria (anti malaria).

Join the conversation


Support Ripples Nigeria, hold up solutions journalism

Balanced, fearless journalism driven by data comes at huge financial costs.

If you are motivated and passionate about building a global society, founded on justice, equity, fairness, transparency, accountability and superior knowledge, kindly consider donating to Ripples Nigeria’s solutions journalism.

Your support would help to ensure that citizens and institutions continue to have free access to credible and reliable information for societal development.

Donate Now

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

17 − 2 =